

Drug Monograph

Drug/Drug **Latuda[®] (lurasidone) Tablet / Atypical Antipsychotic**

Class:

Prepared for: MO HealthNet

Prepared by: ACS, A Xerox Company

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Each 20 mg tablet of Latuda [®] contains 20 mg of lurasidone.	
Manufacturer:	Sunovion Pharmaceuticals Inc. Marlborough, MA 01752 USA	
Indications:	Latuda [®] tablets are an atypical antipsychotic agent indicated for the treatment of patients with schizophrenia.	
Costs:	\$15.39 per tablet of Latuda [®] Wholesale Acquisition Cost	
Summary of Findings:	The Division recommends adding this drug to the current Atypical Antipsychotic Clinical edit.	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input checked="" type="checkbox"/> Clinical Edit	<input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Preferred Agent
	<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Under Solicitation

Prepared By: Katie Wilbers, Pharm.D.
Date: March 5, 2012